Heliyon, Journal Year: 2024, Volume and Issue: 10(9), P. e30312 - e30312

Published: April 26, 2024

Highlights•M774delinsWLV is a rather rare HER2 exon 20 insertion subtype in lung cancer.•Pyrotinib and dacomitinib reveal promising efficacy for M774delinsWLV.•M774delinsWLV reveals no significant structural difference with wild type.•Dacomitinib confers the most potent binding activity to M774delinsWLV.AbstractA775_G776insYVMA, typical predominant variant non-small cell cancer, exhibits relative insensitivity covalent HER2-targeted tyrosine kinase inhibitors. However, other less common insertions have shown better responses M774delinsWLV its clinical sensitivity inhibitors remains unclear. Furthermore, there lack of current studies elucidate structure predict Herein, we presented case cancer harboring who derived favorable response survival benefit from A 60-year-old male metastatic adenocarcinoma carrying received pyrotinib monotherapy as first-line treatment. After rapid disease progression at three months, sequential combination therapy bevacizumab yielded antitumor sustained progression-free benefits nearly year. Subsequent displayed against this uncommon insertion, resulting decrease tumor markers partial response, along one The molecular simulation revealed differences overall protein pocket region between type. Drug dynamics indicated that exhibited compared afatinib, poziotinib. Conclusively, M774delinsWLV. Extensive investigation needed effects on different subtypes.

Language: Английский